Earendil Labs lands $787m to fund biologics development push
Earendil Labs has secured $787m to drive the expansion of its artificial intelligence (AI)-powered drug discovery platform, which has already…
23 Mar 2026
ImmunityBio receives Macau approval for Anktiva combo therapy
ImmunityBio has received approval from the Pharmaceutical Administration Bureau (ISAF) of the Macau Special Administrative Region, China, for Anktiva (nogapendekin alfa inbakicept-pmln) in combination with Bacillus Calmette-Guérin (BCG) for bladder…
23 Mar 2026
BMS secures FDA and EC approvals for Opdivo in Hodgkin Lymphoma
Bristol Myers Squibb’s (BMS) Opdivo (nivolumab) has received approvals for two new indications in classical Hodgkin Lymphoma (cHL) from the US Food and Drug Administration (FDA) and the European Commission…
20 Mar 2026
Novo Nordisk’s Wegovy HD secures FDA greenlight amid patent expiries
Novo Nordisk has landed an approval from the US Food and Drug Administration (FDA) for a high dose version of its best-selling weight loss drug, Wegovy (semaglutide), as patents covering…
20 Mar 2026
Novartis to acquire SNV4818 from Synnovation
Novartis has signed an agreement to acquire SNV4818, a pan-mutant selective Phosphoinositide 3-kinase alpha (PI3Kα) inhibitor, from Synnovation Therapeutics. Under the contract, Novartis will pay $2bn upfront and up to…
20 Mar 2026
Congruence secures $39.5m to advance small molecule correctors pipeline
Congruence Therapeutics has announced the completion of a $39.5m financing round to advance its portfolio of small molecule correctors into the clinic. The portfolio includes programmes targeting melanocortin 4 receptor…
20 Mar 2026
J&J wins FDA approval for Icotyde to enter psoriasis pill market
The US Food and Drug Administration (FDA) has approved Johnson & Johnson’s (J&J) Icotyde (icotrokinra) for the treatment of plaque psoriasis, marking the first US entry of an oral peptide…